BIVV009
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Agglutinin Disease, Cold
Conditions
Agglutinin Disease, Cold
Trial Timeline
Mar 5, 2018 → Oct 5, 2021
NCT ID
NCT03347396About BIVV009
BIVV009 is a phase 3 stage product being developed by Sanofi for Agglutinin Disease, Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT03347396. Target conditions include Agglutinin Disease, Cold.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03347396 | Phase 3 | Completed |
Competing Products
4 competing products in Agglutinin Disease, Cold
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pegcetacoplan + Placebo matching Pegcetacoplan | Swedish Orphan Biovitrum | Phase 3 | 76 |
| sutimlimab | Sanofi | Phase 3 | 76 |
| sutimlimab (BIVV009) + placebo | Sanofi | Phase 3 | 76 |
| Sutimlimab | Recordati | Pre-clinical | 20 |